UK universities prove resilience during Horizon hiatus


Sarah Speight

UK universities prove resilience during Horizon hiatus

Pajor Pawel /

Although UK research universities were going strong after Horizon funding was pulled, it could have been a different story had the scheme not been reinstated, finds Sarah Speight.

Before news broke last week of the new Horizon funding deal for the UK, IP law firm Mathys & Squire reported that the UK’s 50 biggest universities filed 433 new patent applications in the period 2021-2022.

This number fell from 474 in 2020-2021—the year of Brexit and the withdrawal of funding from Horizon Europe—representing a decline of 9%.

Despite the dip, these figures are proof that UK universities continued to be among the world’s most innovative, despite the removal, albeit temporarily, of this valuable source of EU funding.

UK, university, Horizon Pharma, patents, Mathys & Squire, Brexit, innovation, COVID-19, vaccine, MIT, Harvard, biotechnology, pharmaceuticals, technology